Furthermore, in line with what was previously described by Guo et al. in neonatal rat CFs, we showed that FXa enhanced the proliferation of human CFs and that this effect seemed to be attenuated by PAR-1 antagonist [21]. This evidence concerns the gene F10 and myalgic encephalomeyelitis/chronic fatigue syndrome.